MDGEF (Medigene AG) Moat Score: 0/10 (As of Jul. 01, 2026)


MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG Moat Score?

Medigene AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medigene AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medigene AG might have No Moat - No discernible moat.

Medigene AG  (OTCPK:MDGEF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medigene AG Moat Score Related Terms

MDGEF
12GF Score
Medigene AG MDGEF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price